Imbruvica and Diffuse large b-cell lymphoma recurrent - a phase IV clinical study of FDA data

Summary:

Diffuse large b-cell lymphoma recurrent is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Prednisone, and have Diffuse large b-cell lymphoma stage iv.

The phase IV clinical study analyzes which people have Diffuse large b-cell lymphoma recurrent when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Diffuse large b-cell lymphoma recurrent?

Diffuse large b-cell lymphoma recurrent (recurrent cancer of b cells, a type of white blood cell) is found to be associated with 74 drugs and 90 conditions by eHealthMe. Check the latest studies of Diffuse large b-cell lymphoma recurrent.

On Jul, 13, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 34 people (0.05%) have Diffuse large b-cell lymphoma recurrent.

Could Imbruvica cause Diffuse large b-cell lymphoma recurrent?

Among these 34 people:

How long have people been on Imbruvica when they have Diffuse large b-cell lymphoma recurrent? *

What is the gender of people who have Diffuse large b-cell lymphoma recurrent when taking Imbruvica? *

female: 58.06 %
male: 41.94 %

What is the age of people who have Diffuse large b-cell lymphoma recurrent when taking Imbruvica? *

What are other drugs people take besides Imbruvica? *

Prednisone: 22 people, 64.71%
Cytarabine: 21 people, 61.76%
Cyclophosphamide: 19 people, 55.88%
Dexamethasone: 18 people, 52.94%
Vincristine Sulfate: 18 people, 52.94%
Methotrexate: 18 people, 52.94%
Doxorubicin Hydrochloride: 15 people, 44.12%
Temozolomide: 15 people, 44.12%
Bendamustine Hydrochloride: 14 people, 41.18%
Bendamustine: 6 people, 17.65%

What are other side effects people have besides Diffuse large b-cell lymphoma recurrent? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 19 people, 55.88%
Confusion: 18 people, 52.94%
Neurological Symptom (symptoms of nervous system disease): 18 people, 52.94%
Malignant Neoplasm Progression (cancer tumour came back): 18 people, 52.94%
Death: 18 people, 52.94%
Vasogenic Cerebral Oedema (increase in brain water): 18 people, 52.94%
White Blood Cell Count Decreased: 7 people, 20.59%
Haematocrit Decreased: 7 people, 20.59%
Thrombocytopenia (decrease of platelets in blood): 7 people, 20.59%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 7 people, 20.59%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 18 people, 52.94%
Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 18 people, 52.94%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 5.88%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 1 person, 2.94%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Diffuse large b-cell lymphoma recurrent?

- Check whether Diffuse large b-cell lymphoma recurrent is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

Diffuse large b-cell lymphoma recurrent treatments and more:

Diffuse large b-cell lymphoma recurrent (2,790 reports)

How severe was Diffuse large b-cell lymphoma recurrent and when was it recovered:

Diffuse large b-cell lymphoma recurrent in Imbruvica

Expand to all the drugs that have ingredients of ibrutinib:

Diffuse large b-cell lymphoma recurrent and drugs with ingredients of ibrutinib

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diffuse large b-cell lymphoma recurrent:

Diffuse large b-cell lymphoma recurrent (74 drugs)

Browse all the conditions that are associated with Diffuse large b-cell lymphoma recurrent:

Diffuse large b-cell lymphoma recurrent (90 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.